Location History:
- Woodbury, MN (US) (1997 - 2003)
- Hudson, MA (US) (2000 - 2006)
- Somerville, MA (US) (2004 - 2015)
- Cambridge, MA (US) (2015)
- Houston, TX (US) (2013 - 2024)
Company Filing History:
31 out of 1,373 
24 out of 322 
8 out of 2,963 
Years Active: 1997-2024
Areas of Expertise:
Title: Innovations by Gregory D. Cuny in Pharmaceutical Chemistry
Introduction
Gregory D. Cuny, a prolific inventor based in Somerville, MA, is known for his significant contributions to the field of pharmaceutical chemistry. With a remarkable portfolio of 38 patents, Cuny’s work primarily focuses on developing innovative compounds aimed at treating various health disorders, particularly those related to obesity and necroptosis.
Latest Patents
Among Gregory D. Cuny's latest patents are groundbreaking inventions involving phosphatidylcholine transfer protein inhibitors and heterocyclic inhibitors of necroptosis. The first invention discusses compounds represented by Formulas I, II, and III, which serve as inhibitors of phosphatidylcholine transfer protein (PC-TP). This work addresses pharmaceutical compositions and therapeutic methods targeting disorders associated with obesity through the inhibition of PC-TP.
The second patent highlights a series of heterocyclic derivatives designed to inhibit tumor necrosis factor alpha (TNF-α) induced necroptosis. These compounds, detailed in Formulas (I) and (Ia)-(Ie), have been shown to inhibit necroptosis in FADD-deficient human Jurkat T cells. This innovative approach could pave the way for new treatments where necroptosis plays a significant role, showcasing Cuny's dedication to advancing medical science.
Career Highlights
Gregory D. Cuny has worked with prominent organizations, including Sepracor, Inc. and Brigham and Women's Hospital. His tenure at these institutions has provided him with valuable experience and insight into the pharmaceutical industry, which has undoubtedly influenced his prolific inventorship.
Collaborations
Throughout his career, Gregory D. Cuny has collaborated with talented professionals, including James R. Hauske and Brian M. Aquila. These partnerships have fostered innovative research and development efforts, leading to the successful creation of numerous impactful patents in the field.
Conclusion
Gregory D. Cuny’s innovative work and extensive patent portfolio demonstrate his significant impact on pharmaceutical advancements. His inventions hold promise for developing treatments to combat obesity and related disorders, along with other health issues where necroptosis is a critical factor. Cuny’s dedication to research and collaboration continues to inspire future innovations in the field of pharmaceutical chemistry.